Note: This Ask the Expert was recorded prior to Experian’s acquisition of Audigent and discusses industry trends and how we’ve worked together in the past.
Adopting new strategies based on trust due to evolving privacy regulations and the gradual loss of traditional signals, like third-party cookies, is essential to successfully navigating the future of digital advertising. Advertisers and marketers are at a crossroads, facing the challenge of maintaining personalization and precision while respecting consumer expectations around privacy. To stay competitive, brands must adopt future-ready strategies that focus on trust, privacy-forward technologies, and scalable solutions.
In our latest Ask the Expert segment, recorded before Experian acquired Audigent, we explore how first-party data and advanced contextual audience targeting are two critical approaches for successfully navigating these changes. With insights from Greg Williams, President of Audigent, now part of Experian, and Crystal Jacques, VP of Sales at Experian, we discuss how these tools can empower your brand for long-term success.
First-party data as a cornerstone strategy
First-party data, a powerful tool for building meaningful connections with your audience, has emerged as a fundamental pillar of future-ready strategies. When collected and used effectively, it provides brands with a detailed understanding of consumer preferences and behaviors, enabling real-time campaign adjustments for maximum impact.
“Data has become part of every step of the digital advertising supply chain, and should be part of everybody’s buys… the more you can include data in your digital marketing, the better off and the more power you have.”
Greg Williams, President, Audigent
With the continual loss of signal, including third-party cookies, first-party data has proven to be key for brands to stay both competitive and privacy-compliant. Brands using first-party data are better positioned to overcome the challenges of signal loss. This data facilitates improved media targeting and personalized messaging, driving greater engagement and return on investment.
Contextually-Indexed Audiences build relevance
Experian’s Contextually-Indexed Audiences enable advertisers to target users based on their interests in real-time, without relying on cookies or mobile ad IDs. Machine learning analyzes and maps traffic from over two million websites, linking to Experian’s 2,400 audience segments. With added benefits like audience customization and flexible activation through Audigent’s private marketplaces (PMPs) or demand-side platforms, Experian is setting a new standard for scalable audience targeting.
For automotive advertisers, this could mean reaching consumers actively researching luxury electric vehicles on relevant sites. Unlike outdated methods, contextual targeting aligns the message with consumer intent, balancing high precision with consumer privacy.
Automotive success story
Audigent’s innovative solutions have delivered tangible results. Williams mentions how they helped an automotive brand achieve double the scale and triple their goal of driving test drives. This stands as a testament to the real-world effectiveness of contextual audience strategies and Experian’s role in executing them.
How to stay ahead of change
Here are five strategies to help your brand remain future-ready amid privacy challenges and signal loss:
- Prioritize first-party data: Build trust and improve targeting accuracy by relying on data that you own directly from your consumers.
- Test privacy-forward tools: Experiment with solutions like contextual targeting and Google’s Privacy Sandbox to future-proof your advertising.
- Strengthen identity framework: Create systems to securely manage and use data for cross-channel decision making.
- Use scalable tools: Partner with trusted providers to deploy solutions that adapt to changing industry standards.
- Stay proactive and flexible: Continuously evaluate trends and refine approaches to align with emerging consumer and regulatory expectations.
A deeper conversation
For additional insights, watch our full Q&A. Greg Williams and Crystal Jacques discuss the future of audience targeting, how first-party data reshapes marketing strategies, and how Experian and Audigent have collaborated in the past.
About our experts
Greg Williams, President, Audigent
Greg Williams is Audigent’s President, responsible for managing Audigent’s vast portfolio of ecosystem partners, enterprise sales, marketing, and client success. An innovator in programmatic ad buying, Williams co-founded MediaMath and was instrumental in building and scaling that company in the US and internationally. He led MediaMath’s international expansion in 2011 and grew that business from zero to a top revenue driver for the company in three years. During his 14 years at the company, Williams held global roles and built teams across every function of the organization — most notably leading business and market development, product development, and partnerships. Prior to co-founding MediaMath, Williams held senior positions at [X+1] (which was later acquired by RocketFuel), Nielsen, and Accenture.
Crystal Jacques, Head of Enterprise Sales, Experian
Head of Enterprise Partnerships, leading Experian’s go-to-market team across all verticals. With over ten years of experience in the Identity space, Crystal brings a wealth of expertise to her role. She joined Experian in 2020 through the Tapad acquisition, following her successful stint as the head of Global Channel Partnerships for Adbrain, which The Trade Desk later acquired.
Latest posts
Privacy-forward pharma media supports more informed healthcare journeys Effective pharma marketing depends on reaching patients, caregivers, and healthcare professionals (HCPs) with useful information in appropriate, privacy-forward ways. The goal is to make relevant education easier to find, support more informed conversations, and help brands understand how media contributes across the health journey. In this Ask the Expert session, Natalie Mancuso, SVP, Data Partnerships at DeepIntent, joins Sheila Wirick, who leads the health team at Experian, to discuss how to craft patient and HCP campaigns, privacy-safe activation workflows, connected TV (CTV), and measurement approaches built for pharma. Why should your media plan start with understanding the patient and provider The patient-and-provider journey should inform your media plan, as treatment decisions in pharma are increasingly informed, personal, and patient-driven. With more health information available than ever, patients are playing a more active role in understanding their options and participating in treatment conversations. As other industries become more customer-centric, pharma media planning needs to become more patient-centric. “We’ve got patients who are more informed, more involved in their treatment decisions than ever. The accessibility of data and information and the ways we can consume it with just AI alone is so vast that if we’re not arming people with the right information in real time, we’re missing the boat.”Natalie Mancuso, SVP, Data Partnerships This means media should be aligned to where a patient or provider is in the decision journey and what they need at that moment. Early on, media may play an educational role by building awareness of a condition, symptom, or treatment category. Later, it may help support more specific questions, treatment consideration, access, affordability, or adherence. The patient-provider conversation remains the key boundary. That exchange should stay private and clinically led. Media can play a valuable role before and after those moments by offering information that helps patients and providers feel more informed. How can brands connect patient and HCP messaging responsibly? It’s critical for agencies and brands to deliver relevant messaging to inform each stakeholder’s needs throughout the treatment journey, especially ahead of key clinical milestones. To execute this, brands must exercise privacy-forward activation, keeping patient and HCP identity, activation, and measurement paths separate, while using a common workflow layer to support the same brand goal. Experian helps pharma marketers do this by acting as an independent, privacy-forward identity, data, and workflow layer. We bring together high-fidelity matching, governed onboarding, and non-clinical consumer context, so patient and HCP engagement can be activated more accurately across channels and connected to reporting. The distinction is not only where each audience is reached. HCPs may be engaged in both professional and personal environments, but their needs are different from patients’. For example, an HCP may receive messaging about co-pay savings for eligible patients, while a patient may receive information about patient support programs. These are different messages for different audiences, but they ladder up to the same goal: informing both parties in a privacy-forward, relevant way. Hear from Natalie Mancuso in our 2026 State of advertising report In our 2026 State of advertising report, Natalie shares why identity serves as the connective infrastructure that links planning, activation, and measurement across connected TV (CTV), programmatic, commerce media, and walled garden environments. Download the report Watch Natalie’s Q&A What does privacy-forward activation look like in pharma? Pharma brands often start with fragmented patient and HCP signals. Privacy-forward activation turns those inputs into usable audiences by first confirming that the data can be used, then translating identity in controlled environments that protect personally identifiable information through tokenization or other methodologies. For DTC, that means building and matching audiences without relying on inferred health conditions from browsing behavior. For HCPs, it means connecting professional identity to verified sources in a way that supports activation and measurement. In a category shaped by HIPAA, state privacy laws, internal review, and consumer sensitivity, building privacy in from sourcing through activation is what makes responsible health media possible. How can CTV play a more useful role in pharma? CTV can play a more useful role in healthcare when it’s connected to a larger, privacy-forward plan and not treated as just an awareness channel. DeepIntent connects CTV and digital exposure data using identity signals, such as National Provider Identifiers (NPIs), hashed email addresses, IP addresses, device IDs, and household signals, where permitted and reviewed. That identity layer helps support sequencing and suppression across streaming, endemic, mobile, and digital settings. In practice, CTV can introduce targeted education or broad brand awareness, and later touchpoints can provide sequential information in the right channels. Instead of repeating the same message, brands can make pivots based on engagement and context. “For us, it starts with identity and not panels. When we’re resolving CTV and digital exposures to the same person, we’re leveraging signals so that every touchpoint across streaming, endemic, and mobile is recognized as the same individual, not model lookalikes.”Natalie Mancuso, SVP, Data Partnerships For pharma, campaign performance should not be measured by reach alone. A stronger approach looks at whether sequenced engagement contributes to meaningful downstream signals, including: Prescription activity Provider engagement Referral patterns Patient compliance Adherence signals, where measurement is permitted Why should messaging and reporting change in pharma? Pharma campaigns are journeys with changing information needs. Reporting should guide the campaign optimization. “If I’m launching into a market with a new class of drug, I’m asking what education needs to be put into the market – from both an HCP and a consumer standpoint – to build awareness?”Natalie Mancuso, SVP, Data Partnerships Clicks and website visits still have a place, but they can’t tell the full pharma story. DeepIntent processes data in real time, giving brands an up-to-date read on how media connects to campaign engagement. Campaign signals can help teams optimize audience logic, creative, channel mix, or sequencing during a live campaign. Heading Test for Media & Text Block Content Test for Media &Text Block Learn more Heading Test for Media & Text Block Content Test for Media &Text Block Learn more Heading Test for Media & Text Block Content Test for Media &Text Block Learn more Explore how privacy-safe pharma activation can make an impact Experian brings marketing data and identity expertise for health marketing and DeepIntent adds pharma-specific activation experience. Together, we help brands connect patient and HCP strategies responsibly, with privacy built in from the start. Watch the full video with our experts to hear Sheila Wirick and Natalie Mancuso discuss patient and HCP messaging, CTV, privacy-safe activation, and outcome measurement for pharma brands. About our experts Natalie Mancuso SVP, Data Partnerships, DeepIntent Natalie Mancuso is SVP, Data Partnerships at DeepIntent and a leader in health-focused AdTech and DSP strategy. With over 20 years of experience growing billion-dollar healthcare brands, she turns complex data into scalable, performance-driven solutions that keep marketers ahead of industry change. Sheila Wirick Director of Health Sales, Experian Sheila Wirick is the Director of Health Sales at Experian with more than 20 years of experience in data and analytics. As Director of Health Sales at Experian Marketing Services, she collaborates with healthcare, pharmaceutical, and nonprofit organizations to apply data and insights that enhance customer retention, brand awareness, and acquisition. She is committed to helping organizations use data to deliver measurable results and meaningful impact. FAQs What makes a pharma audience activation-ready? A pharma audience is activation-ready when patient or HCP inputs can be translated into usable audiences with the right accuracy, controls, interoperability, and destination readiness. For patient engagement, that may include privacy-safe cohort construction, caregiver logic, non-clinical enrichment and appropriate exclusion rules. For HCP engagement, it may include governed identity inputs such as NPI, specialty, practice location, professional address and other verified attributes where appropriate. How can pharma brands sequence messages across channels responsibly? Pharma brands can sequence messages responsibly by giving each channel a clear role and using audience logic to maintain continuity. CTV and out-of-home can support awareness, social can reinforce the message, search can capture active research and point-of-care or rep-triggered channels can support decision moments. The workflow should preserve separation between patient and HCP identity strategies. What should pharma marketers measure beyond clicks and site visits? Pharma marketers should measure whether media connects to outcomes such as audience quality, prescription activity, qualified HCP engagement, verified delivery, referral patterns, therapy starts or adherence signals where permitted. These outcomes often depend on partner-enabled workflows, clean rooms, and aggregated outputs rather than direct end-to-end tracking. How does Experian help pharma brands connect identity, activation and measurement? Experian acts as an independent privacy-first identity, data, and workflow layer for pharma marketers. We help brands bring together identity, high-fidelity matching, governed onboarding, non-clinical consumer context, and partner interoperability so patient and HCP engagement can be activated more accurately across channels and connected more cleanly to partner-enabled measurement. Latest posts
Heading This is my content Heading This is my content Title sdf sdf sdf sdf sdf sdf sdf
Use case #1: Identifying customer spending potential to boost growth for a retail chain Objective Solution Results The solution By syncing its cookies with the Digital Graph, the DSP gained access to related identifiers, including: This expanded identity universe gave the DSP a unified view of individuals and households, making it possible to connect impressions to conversions across devices and channels. With each weekly refresh, attribution models stayed accurate and up to date, turning fragmented signals into proof of performance. Results Within weeks, the DSP saw measurable improvements